Evidence map›Paper›PMID 40991384›Full record

ArticleCurrent protocols2025

Mouse Models and Experimental Protocols to Study Alloantibody-Mediated Transplant Rejection.

Jason M Zimmerer, Hatem Aldhahi, Ginny L Bumgardner

Abstract read
In one paragraph

Article in Current protocols, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jason M ZimmererDepartment of Surgery, Comprehensive Transplant Center, and the College of Medicine, The Ohio State University, Columbus, Ohio.ORCID https://orcid.org/0000-0002-6091-327X
Hatem AldhahiDepartment of Surgery, Comprehensive Transplant Center, and the College of Medicine, The Ohio State University, Columbus, Ohio.
Ginny L BumgardnerDepartment of Surgery, Comprehensive Transplant Center, and the College of Medicine, The Ohio State University, Columbus, Ohio.ORCID https://orcid.org/0000-0002-3256-0200

Funding

Investigating a Novel Cellular Therapy to Prevent and Treat Acute Antibody Mediated Kidney Transplant RejectionR01AI139913 · NIAID · OHIO STATE UNIVERSITY · PI BUMGARDNER, GINNY L · 2019 to 2023
$2.7M
NIAID NIH HHS R01 AI139913
6 · The paper itself

Abstract

Transplantation is the definitive treatment for patients with end-stage organ failure. Following allogeneic transplant, the recipient's immune system recognizes transplanted cells or organs as foreign. The immune system recognizes and targets the foreign tissue for damage through cell-mediated rejection (CMR) and/or antibody-mediated rejection (AMR). Immunosuppressive agents are utilized to protect the transplant from rejection and extend transplant function and survival. Despite advances in immunosuppressive agents, AMR remains a critical barrier to the success of transplantation. AMR occurs when B cells produce alloantibodies that bind the allograft causing antibody-dependent, complement-mediated or immune cell-mediated cytotoxic damage. Continued research on AMR is required to develop novel and effective therapeutic strategies. Murine AMR models have been utilized to investigate mechanisms mediating the production of posttransplant alloantibodies and the pathology of damage to the transplanted allograft. These models facilitating the investigation of cellular and molecular mechanisms of alloantibody production and allograft damage are critical to the development of novel therapeutic strategies to prevent and treat AMR. This article describes the methodologies used to study AMR in animal transplant models. These include protocols to detect and measure alloantibodies, allograft survival, AMR pathology, and effector immune cell responses following transplantation. © 2025 The Author(s). Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1: Alloserum transfer into immune-incompetent recipient mice to determine transplant organ susceptibility to AMR Basic Protocol 2: Allogeneic transplantation into immune-deficient mice to study critical cellular and molecular pathways impacting AMR Support Protocol 1: Quantification of posttransplant alloantibody titer Support Protocol 2: Monitoring of transplant allograft survival Support Protocol 3: Assessment of immunopathology and severity of AMR Basic Protocol 3: Analysis of posttransplant immunologic responses.

Indexed as

Disease Models, AnimalGraft RejectionIsoantibodiesAnimalsGraft SurvivalMiceIsoantibodiesalloantibodyantibody‐mediated rejectiontransplantation

Identifiers

PMID40991384
PMCPMC12459753

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.